Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485715 | 0.90 | LMNA (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3485691 | 0.89 | IDO1 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3484955 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3485444 | 0.76 | LMNA (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3484953 | 0.76 | L3MBTL1 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL17731134 | 0.75 | DRD4 (0.67) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3454062 | 0.73 | ALDH1A1 (0.73) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3486038 | 0.72 | TSHR (0.59) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3485746 | 0.70 | ALDH1A1 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL3485542 | 0.70 | SMN1; SMN2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | claimed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | claimed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | claimed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | CHRNB2 371/4885CHRNB4 312/4885CHRNA3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.